These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 23063374

  • 1. Cost-minimization analysis of the treatment of patients with metastatic colorectal cancer in Greece.
    Fragoulakis V, Papagiannopoulou V, Kourlaba G, Maniadakis N, Fountzilas G.
    Clin Ther; 2012 Oct; 34(10):2132-42. PubMed ID: 23063374
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
    Hoyle M, Peters J, Crathorne L, Jones-Hughes T, Cooper C, Napier M, Hyde C.
    Value Health; 2013 Oct; 16(2):288-96. PubMed ID: 23538180
    [Abstract] [Full Text] [Related]

  • 3. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
    Lawrence D, Maschio M, Leahy KJ, Yunger S, Easaw JC, Weinstein MC.
    J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
    [Abstract] [Full Text] [Related]

  • 4. Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy.
    Graham CN, Maglinte GA, Schwartzberg LS, Price TJ, Knox HN, Hechmati G, Hjelmgren J, Barber B, Fakih MG.
    Clin Ther; 2016 Jun; 38(6):1376-1391. PubMed ID: 27085587
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
    Vijayaraghavan A, Efrusy MB, Göke B, Kirchner T, Santas CC, Goldberg RM.
    Int J Cancer; 2012 Jul 15; 131(2):438-45. PubMed ID: 21898389
    [Abstract] [Full Text] [Related]

  • 6. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
    Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ, Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group, Australasian Gastrointestinal Interest Group.
    J Natl Cancer Inst; 2009 Sep 02; 101(17):1182-92. PubMed ID: 19666851
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J, Punt CJ.
    Clin Ther; 2010 Mar 02; 32(3):437-53. PubMed ID: 20399983
    [Abstract] [Full Text] [Related]

  • 10. Comparative net cost impact of the utilization of panitumumab versus cetuximab for the treatment of patients with metastatic colorectal cancer in Canada.
    Pettigrew M, Kavan P, Surprenant L, Lim HJ.
    J Med Econ; 2016 Mar 02; 19(2):135-47. PubMed ID: 26442575
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.
    Shiroiwa T, Motoo Y, Tsutani K.
    Mol Diagn Ther; 2010 Dec 01; 14(6):375-84. PubMed ID: 21275455
    [Abstract] [Full Text] [Related]

  • 12. Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.
    Song QB, Wang Q, Hu WG.
    World J Gastroenterol; 2015 Apr 14; 21(14):4365-72. PubMed ID: 25892888
    [Abstract] [Full Text] [Related]

  • 13. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.
    Ann Surg; 2010 Feb 14; 251(2):254-60. PubMed ID: 20010090
    [Abstract] [Full Text] [Related]

  • 14. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C, Frank M, Köhne CH, Hartmann JT, Griebsch I, Mohr A, Osowski U, Schulten J, Mittendorf T.
    Clin Ther; 2011 Apr 14; 33(4):482-97. PubMed ID: 21635994
    [Abstract] [Full Text] [Related]

  • 15. Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.
    Frank M, Mittendorf T.
    Pharmacoeconomics; 2013 Mar 14; 31(3):215-28. PubMed ID: 23338963
    [Abstract] [Full Text] [Related]

  • 16. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.
    Blank PR, Moch H, Szucs TD, Schwenkglenks M.
    Clin Cancer Res; 2011 Oct 01; 17(19):6338-46. PubMed ID: 21807639
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer.
    Carvalho AC, Leal F, Sasse AD.
    PLoS One; 2017 Oct 01; 12(4):e0175409. PubMed ID: 28403233
    [Abstract] [Full Text] [Related]

  • 18. Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.
    Huang F, Xu LA, Khambata-Ford S.
    Clin Cancer Res; 2012 Feb 15; 18(4):1156-66. PubMed ID: 22294722
    [Abstract] [Full Text] [Related]

  • 19. [Cetuximab for patients with metastatic colorectal cancer-from the result of recent clinical trials].
    Ariyama H, Kusaba H, Baba E.
    Gan To Kagaku Ryoho; 2010 May 15; 37(5):782-6. PubMed ID: 20495306
    [Abstract] [Full Text] [Related]

  • 20. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
    Bardelli A, Siena S.
    J Clin Oncol; 2010 Mar 01; 28(7):1254-61. PubMed ID: 20100961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.